Faculty: Krista L. Lanctot, PhD

Krista L. Lanctôt, PhDKrista L. Lanctôt, PhD
Professor of Pharmacology, Psychiatry, University of Toronto
Director, Neuropsychopharmacology, Sunnybrook Health Sciences Center

General Research Areas: Clinical Pharmacology, Neuropharmacology/Psychopharmacology,
Pharmacoeconomics.

Dementia and other neurologic disorders are frequently accompanied by neuropsychiatric symptoms such as aggression, agitation, apathy, depressive symptoms and sleep disturbances. The reason for these symptoms is unknown. Our research aims to elucidate the neurobiology and neuropathology of behavioural disorders associated with neurologic disorders to allow us to understand and predict treatment response. We also look at how medications used to treat behavioural disorders work on the brain.

A second focus is outcomes research, for example how current pharmacotherapies will impact quality of life and interactions between herbal medications used by patients with dementia and prescribed medications.

 

PubMed

Selected Publications:

Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, Wortmann M, Zhong K. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015 Jan;27(1):7-17. doi: 10.1017/S1041610214001963. Epub 2014 Oct 14.PMID: 25311499

Oremus M, Tarride JE, Pullenayegum E, Clayton N, Mugford G, Godwin M, Huan A, Bacher Y, Villalpando JM, Gill SS, Lanctôt KL, Herrmann N; Canadian Willingness-To-Pay Study Group, Raina P. Caregivers' willingness-to-pay for Alzheimer's disease medications in Canada. Dementia (London). 2015 Jan;14(1):63-79. doi: 10.1177/1471301213490709. Epub 2013 Jun 5. PMID: 24339090

Swardfager W, Herrmann N, Mazereeuw G, Lanctôt KL. Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up study. Biol Psychiatry. 2015 Feb 1;77(3):e13-4. doi: 10.1016/j.biopsych.2014.06.006. Epub 2014 Jun 16 PMID: 25034951

Agüera-Ortiz L, Gil-Ruiz N, Cruz-Orduña I, Ramos-García I, Osorio RS, Valentí-Soler M, Olazarán-Rodriguez J, Dobato-Ayuso JL, Lanctôt K, Martínez-Martín P. A novel rating scale for the measurement of apathy in institutionalized persons with dementia: the APADEM-NH. Am J Geriatr Psychiatr  2015 Feb;23(2):149-59. doi: 10.1016/j.jagp.2013.01.079. Epub 2013 Jul 17 PMID: 23871117

MacIntosh BJ, Swardfager WL, Robertson AD, Tchistiakova E, Saleem M, Oh PI, Herrmann N, Stefanovic B, Lanctôt KL. Regional cerebral arterial transit time hemodynamics correlate with vascular risk factors and cognitive function in men with coronary artery disease. AJNR Am J Neuroradiol. 2015 Feb;36(2):295-301. doi: 10.3174/ajnr.A4094. Epub 2014 Aug 21. PMID 25147198

Lai KSP, Herrmann N, Saleem M, Lanctôt KL. Cognitive outcomes following transcatheter aortic valve implantation (TAVI): a systematic review. Cardiovasc Psychiatry Neurol 2015 Feb; 2015: 209569 http://dx.doi.org/10.1155/2015/209569 [ePub 2015 Feb 15] PMID 25785192

Herrmann N, Harimoto T, Balshaw R, Lanctôt KL and the COSID study investigators.  Risk factors for progression of Alzheimer’s disease in a Canadian population: The Canadian Outcomes Study in Dementia (COSID).  Can J Psychiatr  2015 Apr;60(4):189–199 PMID 26174219

Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL. Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 Apr 21;4:CD009524. PMID 25897825

Santiago C, Herrmann N, Swardfager WL, Saleem M, Oh PI, Black SE, Lanctôt KL. White matter microstructural integrity and executive function in coronary artery disease. Am J Ger Psych 2015 Jul;23(7):754-63. doi: 10.1016/j.jagp.2014.09.008. Epub 2014 Sep 28 PMID 25499674 corresponding author  

Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctôt KL. Inflammatory markers in mild cognitive impairment: a meta-analysis. J Alzheimers Dis. 2015 Aug 3;47(3):669-679. DOI: 10.3233/JAD-150042 PMID: 26401702

Liu CS, Lanctôt KL, Chau S, Ruthirakuhan M, Herrmann N.  Cannabinoids for the treatment of agitation and aggression in Alzheimer's Disease: A systematic review. Lead Article. CNS Drugs 2015 Aug;29(8):615-23. doi: 10.1007/s40263-015-0270-y PMID: 26271310

Mazereeuw G, Herrmann N, Xu H, Blanchard AP, Figeys D, Oh PI, Bennett SAL, Lanctôt KL. Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis generating study. Neuropsychiatr Dis Treat 2015 Sep 4;11:2309-2314. doi: 10.2147/NDT.S87111. eCollection 2015. PMID: 26379437

Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL. A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatr Dis Treatment 2015 Sep 29;11:2479-2491. doi: 10.2147/NDT.S89922. eCollection 2015. PMID: 26491326 PMCID: PMC4599178

Eskes G, Lanctôt KL, Herrmann N, Lindsay P, Bayley M, Bouvier L, Dawson D, Egi S, Gilchrist E, Green T, Gubitz G, Hill MD, Hopper T, Khan A, King A Kirton A, Moorhouse P, Smith EE, Green J Foley N, Salter K, Swartz RH on behalf of the Heart and Stroke Foundation Canada Canadian Stroke Best Practices Committees. Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue following Stroke Practice Guidelines, Update 2015 Int J Stroke 2015 Oct;10(7):1130-40. doi: 10.1111/ijs.12557. Epub 2015 Jun 29 doi:10.1111/ijs.12557 PMID 26121596.

Contact:

Sunnybrook Health Sciences Centre 
Neuropsychopharmacology Research 
Room FG-08
2075 Bayview Avenue 
Toronto, Ontario 
M4N 3M5 
Phone: [416]480-6100 X2241 
FAX: [416]480-6022 
Email: krista.lanctot@sunnybrook.ca

Back to Top